Latest News and Press Releases

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American...

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Annamycin is potentially a highly versatile drug capable of working synergistically with numerous...

Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...

27 MARCH 2025                PRESS RELEASE Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025 Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock...

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER